Insider Selling: EXACT Sciences Corp. VP Unloads 7,430 Shares of Stock (EXAS)
EXACT Sciences Corp. (NASDAQ:EXAS) VP Graham Peter Lidgard unloaded 7,430 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $11.07, for a total value of $82,250.10. Following the completion of the transaction, the vice president now directly owns 95,203 shares of the company’s stock, valued at approximately $1,053,897. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
EXACT Sciences Corp. (NASDAQ:EXAS) traded down 0.27% on Wednesday, hitting $11.00. 660,938 shares of the company’s stock traded hands. EXACT Sciences Corp. has a 52-week low of $6.93 and a 52-week high of $14.70. The stock’s 50-day moving average is $12.54 and its 200-day moving average is $11.57. The company’s market cap is $777.7 million.
EXACT Sciences Corp. (NASDAQ:EXAS) last announced its earnings results on Tuesday, October 29th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. During the same quarter last year, the company posted ($0.21) earnings per share. EXACT Sciences Corp.’s revenue was up .0% compared to the same quarter last year. Analysts expect that EXACT Sciences Corp. will post $-0.72 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Maxim Group reiterated a “sell” rating on shares of EXACT Sciences Corp. in a research note to investors on Tuesday. Separately, analysts at Wedbush upgraded shares of EXACT Sciences Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 16th. Finally, analysts at Summer Street initiated coverage on shares of EXACT Sciences Corp. in a research note to investors on Monday, September 16th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.18.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.